Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference


Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that its President and Chief Executive Officer, Steve Mahoney, will present an overview of the company along with its upcoming corporate priorities at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 7:30am PT / 10:30am ET in San Francisco, California. In addition, the company will webcast the question-and-answer breakout session immediately following its presentation at 7:50am PT / 10:50am ET.

The live webcast of the presentation and breakout session can be accessed under "Events and Presentations" on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcast will be available on the company's website following the event.

About Viridian Therapeutics

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian's goal is to advance VRDN-001 as a best-in-class IV therapy followed by VRDN-003 as a first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is also developing additional preclinical assets in autoimmune and rare diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

Source: Viridian Therapeutics, Inc.


These press releases may also interest you

at 14:15
Ediscovery Software Market size is set to grow by USD 13.57 billion from 2024-2028, Rising volume of electronic data to boost the market growth, Technavio
The global Ediscovery software market  size is estimated to grow by USD 13.57 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  15.7%  during the forecast period.  Rising volume of electronic data is...

at 14:03
Maximizing Efficiency and Innovation in Food & Beverage Manufacturing Through Exponential IT Transformation: New Research From Info-Tech Research Group
New research insights from Info-Tech Tech Research Group will equip food and beverage manufacturers with essential strategies for embracing digital transformation. The global research and advisory firm explains that the industry can significantly...

at 13:51
realme Unveils Its Ultra Clear Camera with AI, the realme 13 Pro Series, Pioneering a New Era in AI Imaging
realme, the world's fastest-growing smartphone brand, today unveiled its highly anticipated ultra clear camera with AI, the realme 13 Pro Series, at the realme AI Imaging Media Preview Event in Bangkok....

at 13:30
The Government of Canada is taking steps to address plastic waste and pollution from the textile and apparel sector
Textiles is the fifth-largest category of plastic waste sent to landfills in Canada. Furthermore, through regular wear and tear and when washed, synthetic clothing sheds plastic microfibres?tiny thread-like fibres that become microplastic pollution....

at 13:22
The TADROS brothers, founders of Liberty City, from Montreal, Canada receive the support of a globally recognized billionaire from Silicon Valley for a technology project in Quebec
ÉRIC & DANIEL TADROS, the visionaries behind the Liberty City real estate development, have received support from Tim Draper, a venture capitalist who initially funded Elon Musk for Tesla and SpaceX, and also supported over 20 companies that now...

at 13:13
Beatbot Celebrates Market Leadership with Early Amazon Prime Day Launch and Unbeatable Discounts
Beatbot, the brand behind the world's most innovative pool-cleaning robots, is excited to announce its biggest consumer sale in brand history for Amazon Prime Day 2024. The brand's markdown of smart home technology will run between July 6 and July...

More news about Science and technology...


News published on and distributed by: